MacroGenics, Inc. (MGNX) Financials

MGNX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 298.4 million 145.8 million
2023-09-30 340.0 million 146.0 million
2023-06-30 305.7 million 134.1 million
2023-03-31 343.5 million 234.2 million

MGNX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -28.7 million 4.4 million
2023-09-30 -35.7 million 4.8 million
2023-06-30 -2.4 million 4.4 million
2023-03-31 -13.2 million 4.8 million

MGNX Net Income

No data available :(

MGNX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 229.8 million - 34.0 million
2023-09-30 256.4 million - 34.1 million
2023-06-30 240.3 million - 34.3 million
2023-03-31 241.7 million - 34.5 million

MGNX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 61.9 million
2023-09-30 62.2 million
2023-06-30 62.3 million
2023-03-31 61.8 million

MGNX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 620000 47.4 million 12.6 million -
2023-09-30 499000 30.1 million 12.4 million -
2023-06-30 286000 43.2 million 13.7 million -
2023-03-31 359000 45.9 million 13.5 million -

MGNX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 11.0 million -4.2 million
2023-09-30 10.4 million 85000
2023-06-30 13.1 million 1.2 million
2023-03-31 24.2 million 3.5 million

MGNX

Price: $14.56

52 week price:
4.29
21.88

Payout Ratio Range:
-22.22%
-2.83%

Earnings Per Share: -0.15 USD

P/E Ratio: 21.30

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 382181

Ebitda: -45.8 million

Market Capitalization: 1.1 billion

Links: